Amarin Corp Plc (AMRN)

[Hike]

Amarin prepared to defend patents against Epanova launch, says H.C. Wainwright After speaking with an intellectual property attorney, H.C. Wainwright analyst Andrew Fein believes Amarin (AMRN) has prepared itself to defend its patents for Vascepa against a possible launch of AstraZeneca's (AZN) omega-3 Epanova. The consultation revealed the FDA's Orange Book includes 25 patents listed for Vascepa, Fein tells investors in a research note. While, according to the IP attorney, Amarin's Orange Book patents do not appear to directly address Epanova, Amarin has a large patent portfolio in this space, says the analyst. Fein points out that Amarin could not hypothetically sue AstraZeneca for patent infringement until Epanova was made, used, or sold in a commercial context. These are not brand-generic circumstances between both companies, he writes. However, Fein thinks Amarin's patents could give it the upper hand and he reiterates a Buy rating on the shares with a $51 price target.

Read more at:
https://thefly.com/landingPageNews.php?id=2939428&headline=AMRN;AZN-Amarin-prepared-to-defend-patents-against-Epanova-launch-says-HC-Wainwright